Mode
Text Size
Log in / Sign up
N/A N=50 Randomized Single-blind Treatment

Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants

Respiratory Distress Syndrome · Bronchopulmonary Dysplasia

Enrolled (actual)
50
Serious AEs
0.0%
Results posted
Nov 2018
Primary outcome: Primary: Changes in the Measurements of Functional Residual Capacity (FRC) in Randomized Premature Infants — 12.6; 6.4; 27.2; 17.1 mL — p=<0.05

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
CPAP and room air (Device)
Age
Pediatric
Sex
All
Sponsor
Oregon Health and Science University
Primary completion
May 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Changes in the Measurements of Functional Residual Capacity (FRC) in Randomized Premature Infants
12.6; 6.4; 27.2; 17.1 <0.05 sig
SECONDARY
Measurements of Passive Respiratory Compliance in Randomized Premature Infants
1.37; 1.32; 1.28; 1.17; 1.08; 1.12 >0.05
SECONDARY
Passive Respiratory Resistance in Randomized Premature Infants
0.054; 0.053; 0.061; 0.074; 0.073; 0.082
SECONDARY
Measurements of Tidal Flow Volume Loops Will be Done in the Randomized Premature Infants.
7.1; 7.8; 7.6; 7.4; 7.3; 7.3

Summary

The primary aim of this study is to quantify and compare changes in lung volumes (as measured by functional residual capacity) in premature infants stable on continuous positive airway pressure (CPAP), and then randomized to two additional weeks of CPAP and room air versus room air alone. We hypothesize that infants randomized to additional CPAP will demonstrate an increased functional residual capacity (at the end of the two week study period and prior to discharge) compared to those randomized to room air.

Eligibility Criteria

Inclusion Criteria

  • Gestational age at birth <33 weeks
  • Required CPAP for a minimum of 24 hours for respiratory distress
  • Patient on CPAP and room air at time of randomization

Exclusion Criteria

  • Complex congenital heart disease other than patent ductus arteriosus or atrial septal defect
  • Major malformations or chromosomal anomalies
  • Multiple gestation greater than twins
  • Culture proven sepsis or unstable at time of randomization
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02249143). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search